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PHARMACY NEWS
Take Home dispensing time reduced
To achieve timely dispensing of Take Home,
Pharmacy department initiated a project in which
Take Home orders of specific pharmacies (C1,
C2) have been diverted to a single pharmacy
(Peads) for a specific duration of time (from
12:00-4:00 pm). The concept of Take Home pharmacy has resulted in speedy delivery of Take
Home medications. The mean take home dispensing time was reduced from 50 minutes to 30
minutes.
High alert medications
This policy intends to provide specific written procedures for the safe storage, prescribing, dispensing, administration and handling of
concentrated electrolytes that have been designated as high-alert medications by JCIA . Currently a project has been initiated that involves
dispensing of premixed/diluted High Alert Medications including Potassium Chloride, Potassium
Phosphate, Magnesium Sulfate and Hypertonic
Saline, and 100% beds have been covered
through this.
Poster presentation
Pharmacist Shaukat Ali Muttaqi Shah presented
a poster (Quantitative Analysis of Drug-Drug Interaction in Ambulatory Care Setting) in a congress at Basel, Switzerland. The presentation
was organised by Federation of International
Pharmaceuticals (FIP).
Clinical pharmacy services coverage
The floors covered by clinical pharmacists include:
ICU, CICU, CCU, NICU, Peads, C2 post call,
stroke unit, Gastroenterology, Psychiatry and Oncology. Through pharmacists’ intervention, total
cost avoidance in the year 2008 is:
Rs 9,845,000.
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Reducing errors related to Look Alike Sound
Alike drugs (LASA)
A multidisciplinary project was completed with the
target of reducing the errors associated with
LASA drugs to 50%. The major interventions of
the group to achieve the target were: TALL man
lettering, use of cautionary labels for look-alike
drugs and computer alerts for physician and
nurses for LASA drugs.
Height weight update through Computerised
Physician Order Entry (CPOE)
Patient demographics and related information is
of utmost importance while prescribing drugs and
reviewing the orders. Among these, the height
and weight of patient is a vital and important information based upon which the drugs could be prescribed and dispensed in right dose and
frequency. For ensuring compliance, Pharmacy in
collaboration with IT worked to ensure the availability of this information to users prescribing, reviewing and dispensing the medications. Since
children are more prone to dose variations and
the right dose and frequency is detrimental in
avoiding treatment failure or overdose, the team
selected this group of patients for the implementation of this project in initial phase. Therefore
currently no order for a child would be accepted
by the COPE system if the height and weight information is not updated. A similar process will be
adopted for adult patients in next the phase.

FDA ALERTS
Alert regarding Clopidogrel
Decrease in effectiveness may be due to genetic
differences or because of interference with other
drugs. FDA recommends the following regarding
clopidogrel use:
• Healthcare providers should continue to prescribe and patients should continue to take clopidogrel as directed, because clopidogrel has
demonstrated benefits in preventing blood clots
that could lead to a heart attack or stroke.
• Healthcare providers should re-evaluate the
need for starting or continuing treatment with a
PPI in patients taking clopidogrel.
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Summary of FDA Alerts 2008
Month

Drug(s)

Summary
Increased risk of serious skin reactions including Stevens John-

November

Phenytoin

son syndrome (SJS) and toxic epidermal necrolysis (TEN) from
phenytoin therapy in Asian population
No increased risk of atrial fibrillation in patients treated with a

November

Biphosphonates

bisphosphonate drug
Modified product labels of OTC cough and cold medicines as

October

OTC cough and cold drugs

‘do not use’ for children under 2 years of age
New indications amyotrophic lateral sclerosis (ALS), a neurode-

September

Statins

September

Rituximab

generative disease often referred to as ‘ Lou Gehrig's Disease’

Risk of Progressive multifocal leukoencephalopathy PML
Combination used resulted in large number of cancers and can-

August

Simvastatin/Ezitimibe

cer associated deaths, whereas no additional CVS protection
observed
Dose dependent adverse effects including Rhabdomyolysis,

August

Simvastatin/Amiodarone

muscle injury, renal failure and deaths have been reported with
this combination
Use of Erythropoietin can increase the risks of thrombovascular

July

Erythropoietin

events, shortened time to tumor progression or recurrence, and
shortened survival time
Several cases of microangiopathic hemolytic anemia (MAHA) in

July

Bevacizumab

July

Fluoroquinolone

patients with solid tumors receiving Avastin in combination with
sunitinib malate
Increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolones for systemic use
‘Conventional and atypical antipsychotics’ increases risk of mor-

June

Antipsychotics

May

Mycophenolate Mofetil

tality in elderly patients treated for dementia-related psychosis

Reports of infants born with serious congenital anomalies, including microtia and cleft lip and palate, following exposure to
mycophenolate mofetil (MMF) during pregnancy
Possible association between the use of and behavior/mood

March

Montelukast

February

Heparin Sodium

changes, suicidality (suicidal thinking and behavior) and suicide

Reports of serious adverse events including allergic or hypersensitivity-type reactions, with symptoms of oral swelling, nausea, vomiting, sweating, shortness of breath, and cases of
severe hypotension
Serious neuropsychiatric symptoms, including changes in be-

February

Varenicline

havior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide
Patients receiving antiepileptic drugs had approximately twice

January

Antiepileptics

the risk of suicidal behavior or ideation (0.43%) compared to patients receiving placebo (0.22%)
Possibility of severe and sometimes incapacitating bone, joint,

January

Bisphosphonates

and/or muscle (musculoskeletal) pain in patients taking bisphosphonates
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DRUG SAFETY UPDATE
Amiodarone - Fluconazole
Amiodarone (antiarrhythmic, group III) is a potent
‘membrane active’ cationic amphiphilic compound
which has both polar and nonpolar constituents.
While Fluconazole, a triazole antifungal, acts by
inhibiting the fungal cytochrome P-450 dependent
enzyme, lanosterol-14-alph-demethylase. An Adverse drug reaction occurred due to the simultaneous use of Fluconazole and Amiodarone, that
is QT-prolongation. As concurrent use of amiodarone and fluconazole may result in an increased risk of cardiotoxicity (QT prolongation,
torsades de pointes, cardiac arrest) with severity
is major. Strict cardiac monitoring and caution is
required when used concurrently.

N-Acetylcystein (IV)
To protect kidneys from the toxic effects of dyes
used in different procedures (for example pre and
post catheterisation) Acetylcysteine is one of the
drugs of choice. N-Acetylcysteine (NAC) is given
intravenously pre-op and after that oral doses are
given for 48 hours. An adverse effect of rash followed by phlebitis was reported, when patient
was given intravenous Acetylcysteine post-op
instead of oral. Then by discontinuing IV-NAC
patient recovered from the adverse reaction occurred. Advise: injudicious use of IV NAC may
result in ADRs and hence the proper protocol for
NAC administration should be followed. The
guidelines and research done on the prophylactic
dose of NAC, usually recommends an oral dose
of 600-1200 mg PO Q12h X 4 doses, 2 doses
pre-contrast and 2 doses post-contrast is optimal;
and another option is IV Acetylcysteine 600-1200
mg IV x 1 over 15 minutes, then 600-1200 mg PO
q12h x 4 doses post-procedure along with hydration (IV formulation is available for high risk patient’s with acute ST-elevation MI undergoing
cardiac catheterisation).

Digoxin Toxicity
Digoxin is a cardiac glycoside used in cardiac arrhythmia. Digoxin exerts a positive ionotropic ef-
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fect on both the normal and failing heart, which increases linearly with the dose, and is mediated
through inhibition of transmembranous active
transport of sodium and potassium. Since we do
not have Digoxin Immune Fab available in Pakistan the treatment modalities for Digoxin overdose include anti-arrythmics, charcoal and
cholestyramine. Cholestyramine was found to
have minimal effect on digoxin absorption and excretion in man but was reported to decrease the
serum digoxin half-life from 75.5 hours to 19.9
hours in a 94 year old man with chronic digoxin
toxicity and renal insufficiency.

ESTABLISHMENT OF A NEW
ANTI- H.PYLORI REGIMEN:
SEQUENTIAL THERAPY
According to the American College of Gastroenterology (2007), an alternative dosing regimen is
sequential therapy. Eradication rates exceeding
90% may be achieved with sequential therapy
consisting of a proton pump inhibitor (40 mg daily)
plus amoxicillin (1 g twice daily) for the first 5
days, followed by PPI(20 mg), clarithromycin (500
mg) and tinidazole (500 mg) twice daily for the remaining 5 days or standard 7 days treatment [PPI
(20 mg), clarithromycin (500 mg) and amoxicillin
(1 g) twice daily]. The sequential therapy is well
tolerated by children, adults and elderly patients
and may be superior to clarithromycin-based
triple therapy in patients with clarithromycin-resistant H. pylori infections.

